Making Tradeoffs: Planning Sample Volumes
Executive Summary
What percentage of samples dispensed support their major purpose--encouraging new courses of prescription therapy? The unsettling answer: far more than most people think.
You may also be interested in...
Understanding when and how physicians dispense product samples
Because physicians' use of product samples varies across pharmaceutical classes and products in measurable ways, it behooves drug companies to start assessing how much their sampling is actually boosting market share and how much it is simply cutting their revenue-generating prescriptions.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.